The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia

Stachowiak, Anna; Szałek, Edyta; Karbownik, Agnieszka; Łojko, Anna; Porażka, Joanna; Przewoźna, Iwona; Grabowski, Tomasz; Wolc, Anna; Grześkowiak, Edmund

doi:10.1007/s13318-018-0508-4

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DM has other complications, including increased susceptibility to other diseases, loss of mobility with aging, depression, and pregnancy problems (CDC, 2017). The condition can cause pathophysiological changes in the body that include a reduction in gastric emptying time, albumin glycation, and CYP activity; that affect the pharmacokinetics and pharmacodynamics of drugs (Stachowiak et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have confirmed the influence of diabetes mellitus on the pharmacokinetics of drugs (Stachowiak et al, 2019). Since maintenance of normal blood glucose levels is essential in diabetes monitoring of anti-diabetic drug therapy in the presence of other drugs, the influence of such drugs needs to be evaluated to maintain safety (Kilari et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of dihydro-artemisinin on the pharmacokinetics of gliclazide in diabetic subjects

Ishaku¹,

Bakare-Odunola²,

Musa³

et al. 2020

Int. J. Bio. Chem. Sci

View full text Add to dashboard Cite

Diabetic patients do have co-occurring diseases like malaria, especially in tropical regions. Hence, polypharmacy is sometimes unavoidable. Gliclazide is widely used in the treatment of non-insulin-dependent type 2 diabetes mellitus, while dihydro-artemisinin (DHA) is one of the most promising medications used in the treatment of malaria on account of its good efficacy and tolerability. The study evaluated the effect of DHA on the pharmacokinetics of gliclazide in diabetic patients. This is a single dose one-way, cross-over study in two periods, with each phase preceded by an overnight fast. Six subjects that passed inclusion criteria participated in the study. The volunteers acted as their control. Phase 1 of the study involved administering a single oral dose of 80 mg of gliclazide after an overnight fast. After a washout period of one week, 80 mg gliclazide and 120 mg DHA were co-administered. Serial blood samples were collected at time intervals throughout 24 h and processed. A validated HPLC method was used to estimate serum gliclazide concentration, while the glucose oxidase peroxidase method was used in the evaluation of blood glucose concentration. The Pharmacokinetic Software - PharmPK was used to generate the pharmacokinetic parameters. GraphPad Prism version 7.01 software for window was used for data analysis. Statistical differences observed in the pharmacokinetic profiles of gliclazide and blood glucose concentration were not significant. Single oral dose of gliclazide and dihydro-artemisinin had good safety and tolerability in diabetic subjects. Keywords: Diabetes mellitus, Dihydro-artemisinin, Drug Interactions, Gliclazide, Pharmacokinetics

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of dihydro-artemisinin on the pharmacokinetics of gliclazide in diabetic subjects

Ishaku¹,

Bakare-Odunola²,

Musa³

et al. 2020

Int. J. Bio. Chem. Sci

View full text Add to dashboard Cite

show abstract

Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older

Alchin

Dhar²,

Siddiqui³

et al. 2022

Current Medical Research and Opinion

View full text Add to dashboard Cite

The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia

Abstract: No differences in the pharmacokinetics of APAP, APAP-glu and APAP-sulfate in patients with FN indicates that diabetes does not influence glucuronidation and sulfatation of paracetamol.

Cited by 2 publications

References 14 publications

Effect of dihydro-artemisinin on the pharmacokinetics of gliclazide in diabetic subjects

Effect of dihydro-artemisinin on the pharmacokinetics of gliclazide in diabetic subjects

Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older

Contact Info

Product

Resources

About